A new study by the Medical University of Vienna found that a specialized form of imaging could identify 91% of prostate cancer cases without the need for a biopsy. Traditionally, a blood test can ...

PSMA PET/CT-targeted biopsy detects more clinically significant prostate cancer than systematic biopsy alone in men with ...

PSMA PET/CT-targeted biopsy detects more clinically significant prostate cancer than systematic biopsy alone in men whose MRI findings are ...

A new review in Medical Oncology details how liquid biomarkers, advanced imaging, and artificial intelligence are transforming pre-biopsy discrimination of prostate cancer from benign disease.

A prospective study shows PSMA PET/CT-guided targeted biopsy detects clinically significant prostate cancer in 37 percent of ...

PSMA PET/CT-targeted biopsy detects more clinically significant prostate cancer than systematic biopsy alone in men whose MRI ...

The Canadian Urological Association (CUA) has published a multidisciplinary expert report offering Canadian consensus recommendations on prostate-specific membrane antigen (PSMA) positron emission ...

So far, I have talked about the mechanism of TomoTherapy and how treatment plans are created.Now, how is treatment considered ...

Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians ...

BiPASS for Pre-Biopsy PSMA-PET Imaging in Prostate Cancer / BiPASS, cancer, cancer care, Cancer research, cancer treatment, ...

China’s biopsy device market gains momentum from cancer screening, minimally invasive innovation, hospital upgrades, government support and cost-effective local manufacturingDublin, Sept. 30, 2026 ...

Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver ...